Trigeminal Neuralgia

1. Clinical Overview

Summary

Trigeminal neuralgia (TN) is a chronic neuropathic pain disorder characterised by recurrent, severe, unilateral, electric shock-like facial pain in the distribution of one or more branches of the trigeminal nerve (cranial nerve V). It is considered one of the most severe pain conditions known to medicine, historically referred to as "the suicide disease" due to its devastating impact on quality of life. [1,2]

Classical (idiopathic) TN is most commonly caused by neurovascular compression of the trigeminal nerve root at the root entry zone, typically by the superior cerebellar artery. Secondary TN occurs due to underlying pathology including multiple sclerosis, cerebellopontine angle tumours, arteriovenous malformations, or other structural lesions. [3,4]

The diagnosis is primarily clinical, based on characteristic pain features: paroxysmal attacks lasting seconds to 2 minutes, severe intensity, electric shock-like quality, precipitation by innocuous stimuli (eating, talking, light touch), and presence of a refractory period between attacks. Neurological examination is typically normal in classical TN; any sensory or motor deficit suggests secondary causes. [5,6]

First-line pharmacological treatment is carbamazepine or oxcarbazepine, with initial response rates of 70-80%. Surgical options for medically refractory cases include microvascular decompression (MVD), which offers the highest long-term pain-free rates (70-80% at 10 years), gamma knife radiosurgery, and percutaneous ablative procedures. [7,8,9]

Key Facts

• Incidence: 4-28 per 100,000 per year (varies by population); increases with age. [10]
• Peak Age: 50-70 years; onset before 40 raises suspicion for secondary causes.
• Sex: Female:Male ratio approximately 1.5-1.8:1. [11]
• Distribution: V2 (maxillary) and V3 (mandibular) most commonly affected (> 90%); V1 (ophthalmic) alone rare (less than 5%).
• Aetiology: Neurovascular compression (80-95% classical TN), multiple sclerosis (2-4%), tumour (less than 1%). [3,12]
• First-Line Treatment: Carbamazepine 200-1200mg daily or oxcarbazepine 300-1800mg daily. [7,13]
• Surgical Cure Rate: Microvascular decompression - 80-90% initial pain freedom, 70-80% at 10 years. [14]

Clinical Pearls

"The Suicide Disease": Trigeminal neuralgia causes some of the most severe pain known to medicine. The intensity and unpredictability of attacks can lead to severe depression, social isolation, and historically, suicide - hence the grave moniker. Modern treatment has dramatically improved prognosis.

Trigger Zones: Light touch (e.g., washing face, eating, cold wind) triggers excruciating pain, yet firm pressure often does NOT. This paradox reflects the underlying pathophysiology of ephaptic transmission between mechanoreceptive Aβ fibres and nociceptive fibres.

Refractory Period: After an attack, there is a characteristic refractory period of seconds to minutes during which another attack cannot be triggered. This feature helps distinguish TN from other facial pain syndromes.

Red Flags for Secondary TN: Age less than 40 years, bilateral symptoms, sensory loss, V1 involvement alone, progressive course, or additional cranial nerve signs mandate urgent MRI to exclude multiple sclerosis, cerebellopontine angle tumours, or other structural lesions.

Carbamazepine Response: Dramatic response to carbamazepine is almost pathognomonic for TN and can serve as both therapeutic and diagnostic tool. Failure to respond should prompt reconsideration of diagnosis. [15]

---

2. Epidemiology

Incidence and Prevalence

• Annual Incidence: 4-28 per 100,000 population (variation reflects geographical and methodological differences). [10,11]
• Prevalence: Approximately 0.1-0.3% of the general population.
• Lifetime Risk: Estimated 1 in 15,000 to 1 in 25,000.
• Age Distribution: Incidence increases with age; rare before 40 unless secondary cause.
• Peak Onset: 50-70 years (mean 53-57 years). [11]
• Sex Distribution: Female predominance with F:M ratio 1.5-1.8:1. [11]
• Laterality: Slight right-sided predominance (approximately 1.6:1 right:left ratio).
• Bilateral Disease: Occurs in less than 3% of classical TN; when present, strongly suggests multiple sclerosis. [4]

Classification Systems

ICHD-3 Classification (International Classification of Headache Disorders, 3rd Edition)

Distribution by Nerve Branch

The trigeminal nerve has three major divisions:

Risk Factors and Associations

---

3. Aetiology and Pathophysiology

Aetiology of Trigeminal Neuralgia

Classical (Primary) TN - Neurovascular Compression Theory

Anatomical Basis:

• Site of Compression: Root entry zone (REZ) of trigeminal nerve, 2-4mm from brainstem.
• Significance of REZ: Transition zone between central myelin (oligodendrocytes) and peripheral myelin (Schwann cells); structurally vulnerable point. [3]
• Offending Vessel: Superior cerebellar artery (SCA) in 75-80% of cases; anterior inferior cerebellar artery (AICA) in 10-15%; venous compression in 5-10%. [18]
• Mechanism of Compression: Arterial elongation, tortuosity, and ectasia with aging leads to arterial loop impingement on nerve root. Pulsatile compression causes chronic mechanical injury. [18]

Secondary TN - Identifiable Structural Causes

Molecular and Cellular Pathophysiology

Step 1: Chronic Mechanical Compression

Pulsatile arterial compression at the root entry zone causes:

• Repetitive mechanical deformation of nerve fibres.
• Disruption of blood-nerve barrier.
• Local ischaemia and oxidative stress.

Step 2: Focal Segmental Demyelination

Chronic compression leads to:

• Loss of myelin sheath at site of compression.
• Exposure of naked axons.
• Shortened internodal distances.
• Clustering of sodium channels (Nav1.6, Nav1.7, Nav1.3) at sites of demyelination. [19]

Step 3: Ephaptic Transmission (Cross-Excitation)

Demyelinated adjacent axons develop abnormal electrical communication:

• Ephaptic coupling: Electrical current from one axon depolarises adjacent axon without synaptic transmission.
• Cross-talk between fibre types: Large myelinated Aβ fibres (mechanoreception, light touch) activate adjacent Aδ and C fibres (nociception). [19]
• Clinical consequence: Innocuous mechanical stimuli (light touch, chewing, talking) trigger severe pain paroxysms.

Step 4: Hyperexcitability and Ectopic Impulse Generation

• Lowered threshold: Demyelinated segments develop reduced threshold for action potential generation.
• Spontaneous firing: Ectopic action potentials originate from sites of demyelination.
• Afterdischarges: Single stimulus triggers repetitive firing (explains paroxysmal nature).

Step 5: Central Sensitisation

Chronic painful input leads to secondary changes in central nervous system:

• Trigeminal nucleus sensitisation: Increased excitability of second-order neurons in trigeminal nucleus caudalis. [20]
• Loss of inhibition: Reduced GABAergic inhibition in trigeminal nucleus.
• Wind-up phenomenon: Progressive amplification of pain signals with repeated stimuli.
• Clinical manifestation: Development of concomitant continuous pain in some patients (TN type 2).

Step 6: Refractory Period

After a paroxysm:

• Neuronal hyperpolarisation: Activation of potassium channels leads to afterhyperpolarisation.
• Absolute refractory period: Seconds during which another action potential cannot be generated.
• Clinical consequence: Characteristic refractory period of seconds to minutes between attacks during which trigger zone stimulation does not elicit pain.

Pathophysiology Diagram - Molecular Level

NEUROVASCULAR COMPRESSION
Superior Cerebellar Artery → Trigeminal Nerve Root Entry Zone
                    ↓
         PULSATILE MECHANICAL STRESS
         (Systolic pressure ~120 mmHg)
                    ↓
┌──────────────────────────────────────────────────────┐
│  FOCAL SEGMENTAL DEMYELINATION                       │
│  - Oligodendrocyte damage                            │
│  - Myelin sheath disruption                          │
│  - Axonal membrane exposure                          │
└──────────────────────────────────────────────────────┘
                    ↓
         ION CHANNEL REORGANISATION
         - Nav1.6, Nav1.7, Nav1.3 clustering
         - Reduced activation threshold
                    ↓
┌──────────────────────────────────────────────────────┐
│  EPHAPTIC TRANSMISSION                               │
│  Aβ fibres (touch) → Aδ/C fibres (pain)             │
│  Electrical cross-talk between demyelinated axons    │
└──────────────────────────────────────────────────────┘
                    ↓
         ECTOPIC IMPULSE GENERATION
         Spontaneous action potentials
                    ↓
         PAROXYSMAL PAIN ATTACKS
┌──────────────────────────────────────────────────────┐
│  Light touch → Severe electric shock-like pain       │
│  Duration: seconds to 2 minutes                      │
│  Followed by refractory period                       │
└──────────────────────────────────────────────────────┘
                    ↓
      CHRONIC STIMULATION (months-years)
                    ↓
┌──────────────────────────────────────────────────────┐
│  CENTRAL SENSITISATION                               │
│  - Trigeminal nucleus hyperexcitability              │
│  - Reduced GABAergic inhibition                      │
│  - Wind-up phenomenon                                │
│  → Concomitant continuous pain (TN type 2)           │
└──────────────────────────────────────────────────────┘

Why Carbamazepine Works: Molecular Mechanism

Carbamazepine preferentially targets the pathophysiology of TN:

1. Voltage-gated sodium channel blockade: Binds to inactivated state of Nav channels, preventing repetitive firing. [7]
2. Use-dependent block: Greater effect on rapidly firing neurons (as in TN) than normally firing neurons.
3. Stabilisation of hyperexcitable membranes: Raises threshold for ectopic impulse generation at sites of demyelination.
4. Reduction of ephaptic transmission: Decreases aberrant cross-excitation between fibres.

---

4. Clinical Presentation

Diagnostic Criteria (ICHD-3)

Classical Trigeminal Neuralgia (13.1.1.1)

A. At least three attacks of unilateral facial pain fulfilling criteria B and C.

B. Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the trigeminal distribution.

C. Pain has at least three of the following four characteristics:

1. Recurring in paroxysmal attacks lasting from a fraction of a second to 2 minutes.
2. Severe intensity.
3. Electric shock-like, shooting, stabbing, or sharp in quality.
4. Precipitated by innocuous stimuli to the affected side of the face.

D. No clinically evident neurological deficit.

E. Not better accounted for by another ICHD-3 diagnosis.

Pain Characteristics - Detailed Description

• "electric jolt") | | Intensity | Extremely severe (often 10/10 on pain scale) | One of the most painful conditions known; functionally disabling | | Duration | Seconds to 2 minutes per paroxysm | Brief duration distinguishes from other facial pain; longer duration suggests alternative diagnosis | | Frequency | Variable: few attacks per day to hundreds; may cluster | Paroxysms often occur in clusters lasting weeks to months | | Location | Strictly unilateral; V2/V3 most common | Bilateral symptoms rare (less than 3%); strongly suggest MS if present | | Timing | No circadian pattern; often worse in afternoon/evening | Fatigue and accumulated triggers may play role | | Refractory period | Seconds to minutes post-attack | Cannot re-trigger pain immediately; pathognomonic feature | | Evolution | Remissions early; become shorter over years | Natural history is progressive without treatment |

Trigger Factors

Common Triggers (in order of frequency):

Trigger Zones:

• Discrete areas of skin or mucosa where light touch reliably elicits pain.
• Most commonly perioral (upper lip, nasolabial fold), perinasal, or chin.
• Patients often guard trigger zones, leading to behavioral changes (e.g., eating on unaffected side only, refusing to shave).

Paradox of TN:

• Light touch triggers pain, but firm pressure often does NOT.
• This reflects selective involvement of large myelinated Aβ fibres in ephaptic transmission.

Natural History and Disease Evolution

Early Phase (First 1-5 years)

• Distinct attacks with pain-free intervals.
• Remissions lasting months to years.
• Paroxysms may be seasonal (some report winter exacerbations).
• Trigger zones well-defined.

Progressive Phase (5-10 years)

• Remissions become shorter and less frequent.
• Attacks increase in frequency and intensity.
• Additional divisions may become involved.
• Development of anticipatory anxiety.

Late Phase (> 10 years without treatment)

• Near-continuous or very frequent attacks.
• Some develop concomitant continuous background pain (TN type 2).
• Severe functional impairment: weight loss, dehydration, social isolation.
• High risk of depression and suicidal ideation.

Red Flags - "The Don't Miss" Signs

These features suggest secondary TN and mandate urgent investigation:

---

5. Clinical Examination

Approach to Examination

In classical TN, neurological examination should be completely normal. Any abnormality suggests secondary cause.

General Observation

Inspect for:

• Facial asymmetry (guarding affected side).
• Poor oral hygiene (difficulty brushing teeth).
• Malnutrition/weight loss (avoiding eating).
• Emotional distress, anxiety, depression.
• Tic or grimace during spontaneous attacks (tic douloureux).

Cranial Nerve Examination - Trigeminal Nerve (CN V)

Sensory Testing

Test all three divisions with light touch and pinprick:

Corneal Reflex:

• Stimulus: Gently touch cornea with cotton wisp from side.
• Response: Brisk bilateral blink (afferent V1, efferent VII).
• Red flag: Absent or reduced corneal reflex suggests V1 pathology (CPA tumour, MS).

Motor Testing

Muscles of Mastication (innervated by V3 motor branch):

Jaw Jerk Reflex:

• Technique: Place finger on relaxed jaw; tap finger with tendon hammer.
• Normal: Slight closure or no response.
• Pathological: Brisk jaw jerk (suggests bilateral upper motor neuron lesion above pons).

Other Cranial Nerves

Test adjacent cranial nerves to screen for CPA lesions:

Trigger Zone Testing (Use with Caution)

• Technique: Gently touch suspected trigger zone with cotton wool.
• Response: Patients with TN often refuse or flinch before contact.
• Clinical value: Rarely necessary; diagnosis usually clear from history.
• Warning: May precipitate severe attack; obtain consent; have patient signal to stop.

Key Examination Findings

✅ Classical TN:

• Normal trigeminal sensory examination.
• Normal trigeminal motor examination.
• Normal adjacent cranial nerves.
• Patient may demonstrate guarding behaviors.

❌ Red Flags Requiring Investigation:

• Sensory loss in any trigeminal division.
• Motor weakness (jaw deviation, wasting).
• Absent corneal reflex.
• Other cranial nerve deficits (VII, VIII).
• Cerebellar signs, long tract signs.

---

6. Investigations

Imaging - Essential for All Patients

MRI Brain (Mandatory Investigation)

Indications:

• All patients with suspected TN to exclude secondary causes.
• Rule out MS, tumours, vascular malformations.
• Identify neurovascular conflict in surgical candidates.

MRI Protocol for TN:

Key Imaging Findings:

Classical TN:

• Neurovascular contact at trigeminal REZ (seen in 80-95%). [18]
• Vessel (usually SCA) indenting or distorting nerve root.
• Degree of compression may correlate with symptom severity.
• Note: Neurovascular contact also found in 10-20% of asymptomatic individuals; correlation with clinical features essential.

Secondary TN:

• Demyelinating plaques in pons, trigeminal root, or trigeminal nucleus (MS).
• CPA mass (acoustic neuroma, meningioma, epidermoid cyst).
• Vascular malformation (AVM, cavernoma).
• Trigeminal schwannoma (nerve thickening, enhancement).

Other Investigations

Differential Diagnosis - Alternative Diagnoses to Exclude

---

7. Management

Management Pathway - Overview

DIAGNOSIS OF TRIGEMINAL NEURALGIA
Clinical diagnosis + MRI brain
              ↓
┌──────────────────────────────────────┐
│ EXCLUDE SECONDARY CAUSES             │
│ - Multiple sclerosis                 │
│ - Tumour                              │
│ - Vascular malformation               │
└──────────────────────────────────────┘
              ↓
      ┌───────┴────────┐
      ↓                ↓
CLASSICAL TN      SECONDARY TN
      ↓                ↓
      ↓         Treat underlying cause
      ↓         + symptom management
      ↓
FIRST-LINE MEDICAL TREATMENT
┌──────────────────────────────────────┐
│ CARBAMAZEPINE (first-line)           │
│ Start 100mg BD                       │
│ Titrate to 200-400mg BD              │
│ Max 1600mg/day                       │
│                                      │
│ OR OXCARBAZEPINE (better tolerated)  │
│ Start 150-300mg BD                   │
│ Titrate to 300-600mg BD              │
│ Max 1800mg/day                       │
└──────────────────────────────────────┘
              ↓
      ┌───────┴────────┐
      ↓                ↓
GOOD RESPONSE    INADEQUATE RESPONSE
70-80% patients  or INTOLERABLE SIDE EFFECTS
      ↓                ↓
CONTINUE         SECOND-LINE OPTIONS
Monitor          ┌──────────────────┐
Attempt taper    │ Add or switch to:│
in remission     │ - Gabapentin     │
      ↓          │ - Pregabalin     │
LONG-TERM        │ - Lamotrigine    │
MAINTENANCE      │ - Baclofen       │
                 └──────────────────┘
                       ↓
                  ┌────┴─────┐
                  ↓          ↓
            IMPROVED   REFRACTORY
                          ↓
                  SURGICAL OPTIONS
            ┌──────────┴──────────┐
            ↓                     ↓
    FIT FOR SURGERY        UNFIT/ELDERLY
            ↓                     ↓
    MICROVASCULAR      PERCUTANEOUS/RADIOSURGERY
    DECOMPRESSION      - Gamma Knife
    (Gold standard)    - Balloon compression
                       - Radiofrequency rhizotomy
                       - Glycerol rhizotomy

Medical Management - Pharmacotherapy

First-Line: Carbamazepine [7,13]

Evidence Base:

• Multiple RCTs and Cochrane review support carbamazepine as first-line. [7]
• NNT (Number Needed to Treat) approximately 1.7-1.8 for pain relief vs placebo.
• Initial response rate: 70-80%.
• Dramatic response within 24-48 hours is almost pathognomonic for TN.

Dosing Protocol:

Monitoring:

Side Effects:

Drug Interactions:

• CYP3A4 inducer: Reduces levels of OCP, warfarin, many other drugs.
• Levels increased by: Erythromycin, diltiazem, verapamil, grapefruit juice.
• Levels decreased by: Phenytoin, phenobarbital, rifampicin.

Alternative First-Line: Oxcarbazepine [13]

Advantages over carbamazepine:

• Better tolerated (less dizziness, drowsiness).
• Lower risk of drug interactions (weaker CYP inducer).
• Lower risk of Stevens-Johnson syndrome.
• No need for HLA-B*1502 screening.

Disadvantages:

• Higher risk of hyponatraemia (25-30% vs 10-15% for carbamazepine).
• Slightly less evidence base than carbamazepine.
• More expensive.

Dosing:

Monitoring:

• Same as carbamazepine, with particular attention to sodium levels.

Second-Line Medications

Used as add-on therapy or monotherapy if carbamazepine/oxcarbazepine ineffective or not tolerated.

Combination Therapy:

• Often necessary when monotherapy inadequate.
• Common combinations: Carbamazepine + lamotrigine; carbamazepine + baclofen; gabapentin + carbamazepine.
• Monitor for additive CNS side effects.

Surgical Management

Indications for Surgical Referral

1. Failure of medical therapy: Inadequate pain control despite maximal tolerated doses of ≥2 medications.
2. Intolerable side effects: Cannot tolerate effective doses of medications.
3. Patient preference: Desire for potentially curative treatment.
4. Long-term medication concerns: Concerns about lifelong medication, side effects, drug interactions.

Surgical Options - Comparative Overview

Microvascular Decompression (Jannetta Procedure) [14]

Gold standard surgical treatment for classical TN with neurovascular compression.

Surgical Technique:

1. Approach: Retrosigmoid (posterior fossa) craniotomy; patient in lateral or park bench position.
2. Exposure: Small craniotomy (3-4 cm); open dura; drain CSF from cerebellopontine angle cistern.
3. Microscopic dissection: Identify trigeminal nerve root entry zone; arachnoid dissection.
4. Decompression: Identify offending vessel (SCA in 75-80%); gently separate from nerve.
5. Interposition: Place Teflon sponge/felt between vessel and nerve to maintain separation.
6. Closure: Dural closure; bone flap replacement; scalp closure.

Outcomes: [14]

• Immediate pain freedom: 80-90%.
• Pain-free at 5 years: 70-75%.
• Pain-free at 10 years: 70-80% (best long-term results of any surgical option).
• Recurrence: ~20-30% at 10 years (may be due to new vessel or Teflon migration).

Complications:

Mortality: less than 0.5% in experienced centers.

Patient Selection:

• Classical TN with neurovascular compression on MRI.
• Medically fit for general anaesthesia and craniotomy.
• Younger patients (better long-term outcomes).
• Life expectancy > 5-10 years.

Gamma Knife Radiosurgery [21]

Non-invasive stereotactic radiosurgery targeting trigeminal root.

Technique:

• Focused radiation (70-90 Gy) to trigeminal root entry zone.
• Outpatient procedure; stereotactic frame placed under local anaesthesia.
• MRI-based targeting; single session.

Mechanism:

• Radiation causes focal nerve injury and demyelination, followed by fibrosis.
• Delayed effect: Pain relief develops over weeks to months.

Outcomes:

• Pain freedom at 1 year: 70-85%.
• Pain freedom at 5 years: 50-60%.
• Mean time to response: 4-6 weeks.

Complications:

• Facial numbness: 10-30% (dose-dependent; often delayed by months to years).
• Paraesthesias: 5-10%.
• Very rare: Brainstem radiation injury, tumour induction (theoretical).

Advantages:

• Non-invasive; no general anaesthesia.
• Outpatient procedure.
• Suitable for elderly and medically unfit patients.
• Can be repeated.

Disadvantages:

• Delayed onset of pain relief.
• Lower long-term success vs MVD.
• Higher recurrence rate.

Percutaneous Procedures

Balloon Compression, Radiofrequency Rhizotomy, Glycerol Rhizotomy:

All target Gasserian ganglion in Meckel's cave via percutaneous foramen ovale approach under image guidance (fluoroscopy).

Common to all:

• Short procedure (30-60 minutes).
• General anaesthesia or deep sedation.
• Immediate or rapid pain relief.
• Facial numbness expected (radiofrequency) or common (balloon, glycerol).
• Recurrence risk higher than MVD.

---

8. Prognosis and Outcomes

Natural History Without Treatment

• Spontaneous remissions occur in 50-70% early in disease course, lasting months to years.
• Remissions become progressively shorter over time.
• Attack frequency and intensity increase over years.
• Functional impairment: Weight loss (avoidance of eating), dehydration, poor oral hygiene, social isolation.
• Psychological impact: Depression (30-50% of patients), anxiety, suicidal ideation (historical: "suicide disease").
• Quality of life: Severely impaired; one of the lowest QOL scores of chronic pain conditions.

Treatment Outcomes

Medical Management Outcomes

Predictors of Good Medical Response:

• Early disease (less than 5 years).
• Clear paroxysmal pain without continuous component.
• Good initial response to carbamazepine.

Predictors of Poor Medical Response:

• Long disease duration.
• Development of concomitant continuous pain (TN type 2).
• Multiple previous medications.
• Secondary TN (MS).

Surgical Outcomes Summary

Immediate Pain Freedom:

• MVD: 80-90%
• Percutaneous procedures: 80-95%
• Gamma Knife: 70-85% (delayed)

Long-Term Pain Freedom (10 years):

• MVD: 70-80% (best)
• Gamma Knife: 40-50%
• Percutaneous procedures: 30-40%

Prognostic Factors

Favourable Prognostic Indicators:

• Classical TN with neurovascular compression on MRI.
• Short disease duration (less than 5 years).
• Good response to carbamazepine.
• Younger age (for MVD).
• No continuous background pain.

Unfavourable Prognostic Indicators:

• Secondary TN (MS, tumour).
• Long disease duration (> 10 years).
• Continuous background pain (TN type 2).
• Multiple previous failed surgeries.
• Elderly age with comorbidities.

---

9. Special Populations and Considerations

Multiple Sclerosis-Related TN

• Occurs in 2-5% of MS patients. [4,12]
• Bilateral in up to 30% of MS-related TN (vs less than 3% in classical TN).
• Younger age of onset (mean 40 vs 55 years).
• Often more refractory to medical management.
• Surgical outcomes less favourable:
  • MVD less effective if demyelinating plaque is primary cause (no vascular compression).
  • Gamma Knife may be preferred surgical option.
• Treatment approach: Same medications; consider MS disease-modifying therapies.

Pregnancy and TN

• TN can worsen, improve, or remain stable during pregnancy.
• Medication concerns:
  • "Carbamazepine: Teratogenic (neural tube defects, cardiac malformations); avoid if possible."
  • "Oxcarbazepine: Limited data; likely similar risk to carbamazepine."
  • "Lamotrigine: Lower teratogenic risk; may be preferred."
  • "Gabapentin/Pregabalin: Limited human data."
• Approach: Multidisciplinary care (neurology, obstetrics); risk-benefit discussion; consider non-medication strategies; surgical options generally deferred until after delivery.

Elderly Patients

• Higher incidence in older age groups.
• Medical management preferred initially, but:
  • Higher side effect burden (CNS effects, falls risk).
  • Polypharmacy and drug interaction concerns.
• Surgical options for elderly:
  • "MVD: Higher perioperative risk (cardiac, cerebrovascular); careful patient selection."
  • Percutaneous procedures or Gamma Knife often preferred (lower risk).

---

10. Complications and Quality of Life Impact

Disease-Related Complications

Quality of Life Impact

• TN has one of the lowest quality of life scores among chronic pain conditions.
• SF-36 scores: Physical and mental component scores significantly below general population norms.
• Impact on:
  • "Work: Frequent sick leave, disability, early retirement."
  • "Social functioning: Avoidance of social situations, eating out, conversations."
  • "Relationships: Strain on family and friendships."
  • "Activities of daily living: Basic self-care (washing, brushing teeth) becomes difficult."

---

11. Guidelines and Evidence Summary

Key International Guidelines

Landmark Studies and Evidence

1. Cruccu G, et al. Trigeminal neuralgia. N Engl J Med. 2020;383:754-762. doi:10.1056/NEJMra1914484 [1]

• Comprehensive review of pathophysiology, diagnosis, and treatment.
• Establishes neurovascular compression as primary mechanism in classical TN.

2. Di Stefano G, et al. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014;15:34. doi:10.1186/1129-2377-15-34 [13]

• Real-world outcomes of carbamazepine/oxcarbazepine in 200 patients.
• 70% responded initially; 50% maintained response at 5 years.

3. Wiffen PJ, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD005451. doi:10.1002/14651858.CD005451.pub3 [7]

• Cochrane systematic review confirming carbamazepine efficacy.
• NNT 1.7-1.8 for TN.

4. Barker FG 2nd, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334:1077-1083. doi:10.1056/NEJM199604253341701 [14]

• Landmark study: 1,185 patients, 10-year follow-up after MVD.
• 70% pain-free at 10 years.
• Established MVD as durable surgical option.

5. Cruccu G, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013-1028. doi:10.1111/j.1468-1331.2008.02185.x [15]

• Evidence-based treatment algorithm.
• Carbamazepine Level A evidence; surgical options for refractory disease.

6. Maarbjerg S, et al. Trigeminal neuralgia - a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014;54:1574-1582. doi:10.1111/head.12441 [5]

• Prospective study of 158 TN patients; detailed clinical phenotyping.
• Confirms diagnostic criteria; refines understanding of pain characteristics.

7. Bendtsen L, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26:831-849. doi:10.1111/ene.13950 [22]

• Most recent comprehensive European guideline.
• Updates evidence for medical and surgical management.

---

12. Viva and Exam Preparation

Opening Statement (Viva Voce)

"Trigeminal neuralgia is a chronic neuropathic pain disorder characterised by severe, paroxysmal, unilateral, electric shock-like facial pain in the distribution of one or more divisions of the trigeminal nerve. It is one of the most painful conditions known, with significant impact on quality of life. Classical TN is most commonly caused by neurovascular compression at the trigeminal root entry zone, typically by the superior cerebellar artery. First-line treatment is carbamazepine or oxcarbazepine, with surgical options including microvascular decompression for refractory cases."

High-Yield Exam Points

Diagnostic Criteria (be able to recite):

• At least 3 attacks of unilateral facial pain.
• Duration: Seconds to 2 minutes.
• Severe intensity, electric shock-like.
• Triggered by innocuous stimuli.
• Normal neurological examination.

Red Flags (memorise):

• Age less than 40 years
• Bilateral symptoms
• Sensory loss
• V1 alone
• Other cranial nerve signs

First-Line Treatment:

• Carbamazepine 100mg BD, titrate to 200-400mg BD.
• Efficacy: 70-80% initial response.
• Monitoring: FBC, U&E, LFTs.

Surgical Options:

• MVD: Gold standard; 70-80% pain-free at 10 years.
• Gamma Knife: Non-invasive; elderly/unfit.
• Percutaneous: High initial success, higher recurrence.

Common Examiner Questions with Model Answers

Q1: What is trigeminal neuralgia? A: "Trigeminal neuralgia is a chronic neuropathic facial pain disorder characterised by recurrent paroxysms of severe, unilateral, electric shock-like pain in the distribution of the trigeminal nerve. It typically affects the maxillary or mandibular divisions, lasts seconds to 2 minutes, and is triggered by light touch. The annual incidence is 4-28 per 100,000, with peak onset at 50-70 years."

Q2: What causes trigeminal neuralgia? A: "Classical TN is caused by neurovascular compression of the trigeminal nerve at the root entry zone, most commonly by the superior cerebellar artery in 75-80% of cases. Pulsatile compression causes focal demyelination, leading to ephaptic transmission and ectopic impulse generation. Secondary TN is caused by multiple sclerosis in 2-4%, cerebellopontine angle tumours, or arteriovenous malformations."

Q3: How do you diagnose trigeminal neuralgia? A: "The diagnosis is primarily clinical based on ICHD-3 criteria: at least 3 attacks of unilateral facial pain, lasting seconds to 2 minutes, severe intensity, electric shock-like quality, precipitated by innocuous stimuli, with no clinically evident neurological deficit. I would perform a full neurological examination, which should be normal in classical TN. Any abnormality suggests a secondary cause. MRI brain is essential to exclude structural lesions."

Q4: What investigations would you request? A: "MRI brain is mandatory for all patients to exclude secondary causes. I would request high-resolution sequences including CISS or FIESTA to visualise neurovascular compression, T2-weighted to detect MS plaques, and T1-weighted with contrast to identify tumours. Before starting carbamazepine, I would check baseline FBC, U&E, LFTs, and sodium. In Asian patients, HLA-B*1502 genotyping is important due to Stevens-Johnson syndrome risk."

Q5: What is your first-line treatment? A: "First-line treatment is carbamazepine, which has Level A evidence from multiple RCTs and Cochrane reviews. I would start at 100mg twice daily and titrate by 100-200mg every 2-3 days to a typical maintenance dose of 200-400mg twice daily, up to a maximum of 1600mg/day. Initial response rate is 70-80%. I would monitor FBC, U&E, and LFTs at baseline, 2 weeks, 3 months, then 6-monthly. An alternative is oxcarbazepine, which is better tolerated but has higher hyponatraemia risk."

Q6: What are the surgical options for refractory trigeminal neuralgia? A: "For medically refractory TN, the gold standard is microvascular decompression via a retrosigmoid craniotomy. The offending vessel, typically the superior cerebellar artery, is separated from the trigeminal nerve root entry zone with a Teflon sponge. This provides 80-90% immediate pain freedom and 70-80% pain-free at 10 years, the best long-term results. However, it carries small risks including hearing loss (1-3%), CSF leak, and less than 0.5% mortality. For elderly or unfit patients, Gamma Knife radiosurgery or percutaneous procedures like balloon compression or radiofrequency rhizotomy are options, with lower immediate risk but higher recurrence rates."

Q7: What are the red flags that suggest secondary trigeminal neuralgia? A: "Red flags include age less than 40 years, bilateral symptoms, sensory loss or numbness, V1 involvement alone, progressive symptoms, other cranial nerve involvement, and poor response to carbamazepine. These features suggest secondary causes such as multiple sclerosis, cerebellopontine angle tumours, or arteriovenous malformations, and mandate urgent MRI with contrast."

Common Mistakes (What Fails Candidates)

❌ Stating TN examination shows sensory loss: Classical TN has normal examination; sensory deficit indicates secondary cause.

❌ Missing red flags: Failing to identify age less than 40, bilateral symptoms, or other CN signs.

❌ Not requesting MRI: MRI is essential for all patients to exclude secondary causes.

❌ Wrong first-line treatment: NSAIDs, opioids, or gabapentin are NOT first-line; carbamazepine is.

❌ Forgetting monitoring: Must mention FBC, U&E, LFTs monitoring with carbamazepine.

❌ Confusing TN types: Classical TN has vascular compression; secondary TN has structural lesion (MS, tumour).

---

13. Patient and Layperson Explanation

What is Trigeminal Neuralgia?

Trigeminal neuralgia (TN) is a condition that causes sudden, extremely severe, electric shock-like pain in your face. The pain follows the path of the trigeminal nerve, which carries feeling from your face to your brain. It usually affects one side of the face, most commonly the cheek, jaw, or lips.

TN is often called "the suicide disease" because the pain is so severe and unpredictable that it can cause severe depression. However, modern treatments are very effective for most people.

What Causes It?

The most common cause is a blood vessel (usually an artery) pressing on the trigeminal nerve near where it enters the brain. Over time, this pressure damages the protective coating of the nerve (like insulation on a wire), causing it to misfire and send pain signals when it shouldn't.

Other less common causes include multiple sclerosis (a condition that affects the nervous system) or, rarely, a brain tumour.

What Does the Pain Feel Like?

• Quality: Like an electric shock, shooting, or stabbing pain.
• Intensity: Extremely severe - often described as the worst pain imaginable.
• Duration: Each attack lasts a few seconds to a couple of minutes.
• Frequency: Can happen many times a day, or there may be pain-free periods lasting weeks or months.
• Location: Usually one side of the face, often the cheek, jaw, or lips.

What Triggers the Pain?

Everyday activities can trigger the pain:

• Touching your face or washing your face.
• Eating, chewing, or drinking.
• Talking or smiling.
• Brushing your teeth.
• Cold air or wind on your face.
• Shaving or applying makeup.

Many people with TN start avoiding these activities, which can lead to weight loss, poor dental health, and social isolation.

How is it Diagnosed?

Your doctor will ask detailed questions about your pain and examine your nervous system. The examination should be completely normal in typical TN; any abnormality suggests another cause.

You will need an MRI scan of your brain to:

• Check for other causes of facial pain (like multiple sclerosis or a tumour).
• Look for a blood vessel pressing on the nerve (if you might need surgery).

How is it Treated?

Medication (First Choice)

The main treatment is a medication called carbamazepine (brand name Tegretol). It works by calming down the misfiring nerve.

• Your doctor will start with a low dose and gradually increase it.
• Most people (70-80%) get good pain relief from this medication.
• You'll need regular blood tests to check for side effects.
• Common side effects include drowsiness, dizziness, and nausea, which often improve over time.

If carbamazepine doesn't work or causes side effects, other medications include oxcarbazepine, gabapentin, pregabalin, or lamotrigine.

Surgery (If Medication Doesn't Work)

If medications don't control the pain or cause intolerable side effects, surgery can help:

Microvascular Decompression (MVD):

• Brain surgery to separate the blood vessel from the nerve.
• Highest success rate: 70-80% of people are pain-free 10 years after surgery.
• Requires general anaesthesia and a small opening in the skull.
• Suitable for younger, fit patients.

Gamma Knife Radiosurgery:

• Focused radiation treatment to the nerve; non-invasive.
• Outpatient procedure with no cutting.
• Pain relief develops over weeks to months.
• Suitable for older patients or those who can't have brain surgery.

Percutaneous Procedures:

• Needle procedures to deliberately damage part of the nerve to stop pain.
• Quick procedures with immediate pain relief.
• Can cause facial numbness.
• Suitable for older patients or those unfit for major surgery.

What is the Outlook?

• Most people get good pain relief with medication or surgery.
• Some people have spontaneous remissions (pain-free periods) without treatment.
• Over time, the condition tends to worsen if untreated, with shorter remissions and more frequent attacks.
• Modern treatments mean most people can live normal lives.

When to Seek Urgent Help

Contact your doctor urgently if:

• You develop sudden, severe facial pain for the first time.
• You're under 40 years old (need extra tests to rule out other causes).
• You develop numbness, weakness, or vision problems.
• Your pain is on both sides of your face.
• Your treatments stop working.
• You're feeling depressed or having thoughts of self-harm.

Living with Trigeminal Neuralgia

• Take medications exactly as prescribed.
• Attend regular follow-up appointments and blood tests.
• Keep a pain diary to track triggers and patterns.
• Join support groups (TN Association, Facial Pain Association).
• Communicate with your doctor about treatment concerns.
• Seek psychological support if needed for depression or anxiety.

---

14. References

Primary Sources

1. Cruccu G, Di Stefano G, Truini A. Trigeminal neuralgia. N Engl J Med. 2020;383(8):754-762. doi:10.1056/NEJMra1914484
2. Jones MR, Urits I, Ehrhardt KP, et al. A comprehensive review of trigeminal neuralgia. Curr Pain Headache Rep. 2019;23(10):74. doi:10.1007/s11916-019-0810-0
3. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124(Pt 12):2347-2360. doi:10.1093/brain/124.12.2347
4. Truini A, Prosperini L, Calistri V, et al. A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology. 2016;86(22):2094-2099. doi:10.1212/WNL.0000000000002720
5. Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. Cephalalgia. 2017;37(7):648-657. doi:10.1177/0333102416687280
6. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
7. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;2014(4):CD005451. doi:10.1002/14651858.CD005451.pub3
8. Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ Clin Evid. 2014;2014:1207. PMID: 25348200
9. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review). Neurology. 2008;71(15):1183-1190. doi:10.1212/01.wnl.0000326598.83183.04
10. Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990;27(1):89-95. doi:10.1002/ana.410270114
11. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2009;147(1-3):122-127. doi:10.1016/j.pain.2009.08.023
12. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology. 1995;45(7):1294-1296. doi:10.1212/wnl.45.7.1294
13. Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014;15:34. doi:10.1186/1129-2377-15-34
14. Barker FG 2nd, Jannetta PJ, Bissonette DJ, Larkins MV, Jho HD. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334(17):1077-1083. doi:10.1056/NEJM199604253341701
15. Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-1028. doi:10.1111/j.1468-1331.2008.02185.x
16. Cheng JS, Lim DA, Chang EF, Barbaro NM. A review of percutaneous treatments for trigeminal neuralgia. Neurosurgery. 2014;10 Suppl 1:25-33. doi:10.1227/NEU.0000000000000011
17. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain. 1994;56(2):127-138. doi:10.1016/0304-3959(94)90086-8
18. Helbig GM, Callahan JD. Use of FIESTA MR imaging for the identification of the neurovascular interface in patients with trigeminal neuralgia. AJNR Am J Neuroradiol. 2009;30(8):1551-1555. doi:10.3174/ajnr.A1572
19. Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain. 2002;18(1):4-13. doi:10.1097/00002508-200201000-00002
20. Obermann M, Yoon MS, Ese D, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology. 2007;69(9):835-841. doi:10.1212/01.wnl.0000269670.30045.6b
21. Régis J, Metellus P, Hayashi M, Roussel P, Donnet A, Bille-Turc F. Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia. J Neurosurg. 2006;104(6):913-924. doi:10.3171/jns.2006.104.6.913
22. Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19(9):784-796. doi:10.1016/S1474-4422(20)30233-7

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current local guidelines. This content is designed for postgraduate medical examinations (MRCP, FRCS, FRACP) and clinical practice.